drugset

drugset / Trial / NCT04869137

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

NCT04869137 ↗

Phase 2 Active not recruiting 26 enrolled H. Lee Moffitt Cancer Center and Research Institute Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.

Timeline

Start: 2021-05-28
Primary completion: 2025-09-13
Completion: 2026-09

Publications

Brohl AS, Sondak VK, Wuthrick EJ, Kim Y, Eroglu Z, Markowitz J, Tarhini AA, Fan W, Martin J, Sneed L, Perez MC, Sarnaik A, Harrington M, Neves RI, Gonzalez RJ, Cruse CW, Zager JS, Tsai KY, Khushalani NI. Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. J Immunother Cancer. 2026 Jan 14;14(1):e013939. doi: 10.1136/jitc-2025-013939.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenvatinib	Small molecule	20 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Indications